Coronavirus infection. Coronavirus infection, unspecified
Conditions
Interventions
Intervention 1: The first intervention group is the patients that will intake 0.2 mg / kg body weight daily Ivermectin orally (3 mg tablets) as a single dose. Intervention 2: Control group will receiv
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Hospitalized patient with positive corona test
Exclusion criteria
Exclusion criteria: Allergic history to Metronidazole or Ivermectin or hypersensitivity reaction to them during trial. pregnant patients COPD Patients suspected to ILD long history of diabetes cirrhotic patients Epileptic patients patients with sever renal failure ang GFR below 20 participating in another RCT
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main consequences of this trial including; the time of disappearance of shortness of breath, the need for oxygen, the reduction of CRP, the normalization of lymphopenia that will be measured by specialists. Also, the effectiveness of each treatment method will be measured based on the length of hospital stay, the likelihood of hospitalization in the ICU, and the likelihood of mortality. Timepoint: Before starting treatment and at the time of discharge, which should not be less than 5 days. Method of measurement: Blood factors with laboratory methods. Temperature with digital thermometer. Blood pressure with mercury sphygmomanometer or digital pulse oximeter. Other cases with direct observation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHassan Joulaei
Shiraz University of Medical Sciences
Outcome results
None listed